Assembly Biosciences, Inc. (NASDAQ:ASMB) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday.
According to Zacks, “Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly’s product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York. “
ASMB has been the topic of several other reports. Chardan Capital reissued a “buy” rating on shares of Assembly Biosciences in a research note on Sunday, September 17th. BidaskClub raised shares of Assembly Biosciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 3rd.
Assembly Biosciences (NASDAQ:ASMB) traded down 0.31% during midday trading on Tuesday, hitting $35.07. The stock had a trading volume of 91,827 shares. The stock’s market cap is $608.96 million. The firm has a 50 day moving average price of $30.21 and a 200 day moving average price of $25.01. Assembly Biosciences has a one year low of $10.37 and a one year high of $36.31.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2017/10/10/assembly-biosciences-inc-asmb-upgraded-to-hold-by-zacks-investment-research.html.
Hedge funds and other institutional investors have recently bought and sold shares of the company. FNY Partners Fund LP acquired a new position in shares of Assembly Biosciences in the first quarter worth $140,000. Nationwide Fund Advisors acquired a new position in shares of Assembly Biosciences in the second quarter worth $161,000. Parametric Portfolio Associates LLC acquired a new position in shares of Assembly Biosciences in the first quarter worth $226,000. Renaissance Technologies LLC acquired a new position in shares of Assembly Biosciences in the first quarter worth $242,000. Finally, Legal & General Group Plc acquired a new position in shares of Assembly Biosciences in the second quarter worth $212,000. 72.27% of the stock is currently owned by institutional investors and hedge funds.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
What are top analysts saying about Assembly Biosciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Assembly Biosciences Inc. and related companies.